Federal Register: HHS Notices · October 28, 2026 · Primary source
Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management; Draft Guidance for Industry; Availability
Read the full document at Federal Register: HHS Notices.
What this may mean
Niche gene-therapy manufacturing guidance; limited to sponsors of individualized GE products, not applicable to most providers or payors.
Informational only. Not legal, medical, financial, or other professional advice. Always consult a qualified professional familiar with your specific facts before relying on any item.
Related items
- Federal Register: HHS Notices · October 30, 2026Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug SubstancesScore 70
- Federal Register: HHS Notices · October 21, 2026No Adjustment to HHS Civil Monetary Penalty Amounts for 2026Score 60
- Federal Register: HHS Notices · October 30, 2026Essential Drug Delivery Performance Characteristics for Devices Intended To Deliver Drugs and Biological Products; Revised Draft Guidance for Industry; AvailabilityScore 30
- Federal Register: HHS Notices · October 23, 2026HHS Approval of Entities That Certify Medical Review OfficersScore 30
- Federal Register: HHS Notices · October 20, 2026New Dietary Ingredient (NDI) Notifications and Related Issues; Identity and Safety Information About the NDI: Guidance for Industry; AvailabilityScore 30
- Federal Register: HHS Notices · October 23, 2026Request for Public Comment: 60-Day Notice for Reinstated Collection: Division of Urban Indian Affairs Uniform Data System and Budget FormulationScore 28